论文部分内容阅读
目的观察和评价伊立替康(CPT-11)联合氟尿嘧啶(5-Fu)与亚叶酸钙(LV)双周方案(FOLFIRI)治疗胃癌术后转移的临床疗效和不良反应情况。方法对62例胃癌术后转移患者采用FOLFIRI双周方案治疗,剂量为CPT-11180mg/m2,静脉滴入90min,d1;LV200mg/m2,静脉滴入,d1,d2;5-Fu400mg/m2,静脉推注,d1,d2;5-Fu600mg/m2,持续静脉滴入22h,d1,d2;14d为1个周期。结果 59例患者可评价疗效,其中CR2例,PR19例,SD26例,PD12例,有效率35.6%。不良反应主要为中性粒细胞减少、胆碱能综合征及延迟性腹泻。结论对于胃癌术后转移患者,FOLFIRI双周方案疗效肯定,不良反应可耐受,有重要的临床应用价值。
Objective To observe and evaluate the clinical efficacy and side effects of irinotecan (CPT-11) combined with 5-fluorouracil (5-Fu) and levofloxacin (LV) Methods Sixty-two patients with postoperative metastasis of gastric cancer were treated with FOLFIRI biweekly. The dose was CPT-11180mg / m2, intravenously for 90min, d1; LV200mg / m2, intravenous infusion, d1, d2; 5-Fu400mg / Bolus, d1, d2; 5-Fu600mg / m2, continuous intravenous infusion of 22h, d1, d2; 14d for a cycle. Results 59 patients can evaluate the curative effect, including CR2 cases, PR19 cases, SD26 cases, PD12 cases, the effective rate was 35.6%. Adverse reactions are mainly neutropenia, cholinergic syndrome and delayed diarrhea. Conclusion For patients with postoperative metastasis of gastric cancer, FOLFIRI biweekly regimen is effective and tolerable adverse reactions, and has important clinical value.